Alessandro A. Viansone, MD, notes how the DESTINY-Breast11 trial could support a move away from anthracycline-based therapy in HER2-positive breast cancer.
Alessandro A. Viansone, MD
Advertisement
Alessandro A. Viansone, MD, is a medical oncologist at Gustave Roussy
Articles by Alessandro A. Viansone, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Early mRNA Vaccine Data Excite Possibilities of Long-Term PDAC Remissions
2
FDA Flashback: GI Cancer Decisions and News From July 2026
3
TNFR2 Advances as a Novel Target for Restoring Antitumor Immunity Across Lymphoma and Solid Tumors
4
Expanding Options and Long-Term Data Reshape Frontline and Emerging CLL Treatment Strategies
5